Want to see IN:VIYASH full AI Analyst Report?
VIYASH Stock Chart & Stats
₹210.65
-₹3.94(-2.00%)
At close: 4:00 PM EST
₹210.65
-₹3.94(-2.00%)
Day’s Range― - ―
52-Week Range₹178.40 - ₹297.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)561.91K
Market Cap
₹107.86B
Enterprise Value₹85.83K
Total Cash (Recent Filing)₹2.59B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)58.3
Beta1.31
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)4.19
Shares Outstanding441,627,660
10 Day Avg. Volume137,962
30 Day Avg. Volume561,909
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.55
Revenue Forecast (FY)₹38.99B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin AccelerationThe sharp 2026 revenue acceleration, combined with improving EBIT and EBITDA margins, indicates stronger operating scale and improved profitability. If this performance persists, the business may be able to convert growth into greater earnings power and reinvestment capacity over the next several quarters.
Improved Balance SheetThe substantial reduction in leverage materially strengthens financial resilience and gives the company more flexibility to fund operations or pursue growth. Expanding equity and renewed positive return on equity further support a healthier capital structure than in the prior reporting periods.
Cash Flow RecoveryThe return to positive and sharply improving free cash flow is an important step toward stronger self-funding capability. Higher operating cash flow can support investment and reduce reliance on external financing, although the durability of this recovery still depends on improved conversion quality.
Bears Say
Weak Cash ConversionCash generation has improved, but the gap between reported earnings and free cash flow suggests that profitability is not yet converting efficiently into deployable cash. Continued sensitivity to working capital or capital spending could limit funding flexibility and make earnings quality less dependable.
Volatile ProfitabilityThe sequence of losses, low profitability, and subsequent rebound shows that the cost structure and earnings profile have not yet demonstrated consistent stability. Margin volatility can make future performance harder to forecast and may reduce confidence that recent improvements will persist through the cycle.
Inconsistent Returns HistoryAlthough return on equity has recovered, the recent period of negative returns indicates that the enlarged equity base has not consistently produced attractive operating outcomes. Sustained positive returns will be needed to validate the balance-sheet improvement and demonstrate durable capital efficiency.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific Limited’s price range in the past 12 months?
Viyash Scientific Limited lowest stock price was ₹178.40 and its highest was ₹297.90 in the past 12 months.
What is Viyash Scientific Limited’s market cap?
Viyash Scientific Limited’s market cap is ₹107.86B.
When is Viyash Scientific Limited’s upcoming earnings report date?
Viyash Scientific Limited’s upcoming earnings report date is Nov 14, 2026 which is in 47 days.
How were Viyash Scientific Limited’s earnings last quarter?
Viyash Scientific Limited released its earnings results on Aug 11, 2026. The company reported ₹1.49 earnings per share for the quarter, missing the consensus estimate of ₹2 by -₹0.51.
Is Viyash Scientific Limited overvalued?
According to Wall Street analysts Viyash Scientific Limited’s price is currently Overvalued.
Does Viyash Scientific Limited pay dividends?
Viyash Scientific Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of 0.22%. See more information on Viyash Scientific Limited dividends here
What is Viyash Scientific Limited’s EPS estimate?
Viyash Scientific Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viyash Scientific Limited have?
Viyash Scientific Limited has 441,627,660 shares outstanding.
What happened to Viyash Scientific Limited’s price movement after its last earnings report?
Viyash Scientific Limited reported an EPS of ₹1.49 in its last earnings report, missing expectations of ₹2. Following the earnings report the stock price went down -4.511%.
Which hedge fund is a major shareholder of Viyash Scientific Limited?
Currently, no hedge funds are holding shares in IN:VIYASH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viyash Scientific Limited
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Glenmark Life Sciences Limited
―
Strides Pharma Science Ltd
―